Observational study of darolutamide in patients with non-metastatic castration-resistant prostate cancer. DAROL
OBSERVATIONAL STUDY WITH PROSPECTIVE FOLLOW-UP DRUGS
Clinical trial information
- Promoter: BAYER HISPANIA SL
- Execution start: 03/12/2021
- End of execution: 30/09/2026
- PI: FERNANDO VAZQUEZ ALONSO